Slingshot members are tracking this event:

Celgene and LYSARC Provide Update on the Phase III ‘REMARC' Study of REVLIMID Maintenance Treatment in Patients with Diffuse Large B-Cell Lymphoma Responding to First-Line R-CHOP Therapy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details REMARC achieved the primary endpoint of a statistically significant improvement in progression-free survival for patients receiving REVLIMID. The interim analysis of overall survival, a key secondary endpoint, showed no benefit in the REVLIMID arm. Based upon these interim results, Celgenedoes not currently plan to seek approval for this indication.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 25, 2016
Related Keywords Remarc Study, Revlimid, Diffuse Large B-cell Lymphoma, R-chop Therapy, Lymphoma Study Association, Chop Chemotherapy, Rituximab